Announcements Trials
Browse Landscape

Phase

Phase 1/2 3Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, T-Cell, Cutaneous 12Lymphoma 9Lymphoma, T-Cell 8Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Hematologic Neoplasms 3Urinary Bladder Neoplasms 2Sezary Syndrome 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Neoplasms 2Neoplasm Metastasis 2Lymphoma, Non-Hodgkin 2Lymphoma, Extranodal NK-T-Cell 2Lymphoma, B-Cell, Marginal Zone 2Lung Neoplasms 2Leukemia, Myeloid, Acute 2Immunoblastic Lymphadenopathy 2Enteropathy-Associated T-Cell Lymphoma 2Colorectal Neoplasms 2Breast Neoplasms 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Thrombocythemia, Essential 1

Interventions

Cyclophosphamide 48Filgrastim 21fludarabine phosphate 19Rituximab 19Etoposide 19Peripheral Blood Stem Cell Transplantation 17fludarabine 16Prednisone 16Vincristine 15Cytarabine 12Doxorubicin 11blinatumomab 8Methotrexate 8Dexamethasone 8Cyclosporine 8Bortezomib 8venetoclax 7Vorinostat 7Paclitaxel 7Melphalan 7Lenalidomide 7Calcium Dobesilate 7Biopsy 7Specimen Handling 6Radiotherapy 6Indium 6tanespimycin 5aldesleukin 5Tacrolimus 5Inotuzumab Ozogamicin 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Burkitt Lymphoma × romidepsin × Clear all
NCT01897012 2019-01-28

Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas

National Cancer Institute (NCI)

Phase 1 Completed
26 enrolled
Lymphoid

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Follicular, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡